SEC Tracker
Get the app

Viatris VTRS

Viatris Q3 FY25: revenue $3.8B, flat; diluted EPS −$0.11

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Viatris reported for Q3 FY25, the quarter ended Sep 30, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$3.8BFlat against $3.8B in Q3 FY2410-Q income statement, on EDGAR
  2. Diluted EPS−$0.11−237% from $0.08 in Q3 FY2410-Q income statement, on EDGAR
  3. Cash and cash equivalents$975.3M−48% from $1.9B in Q3 FY2410-Q balance sheet, on EDGAR
  4. Cash from operations$744.9M−10% from $826.5M in Q3 FY2410-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Viatris files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Roivant Sciences ROIV public float $9.8B, Sep 30, 2025
  2. United Therapeutics UTHR public float $11.2B, Jun 30, 2025
  3. Neurocrine Biosciences NBIX public float $9.5B, Jun 30, 2025
  4. Exelixis EXEL public float $9.4B, Jul 4, 2025
  5. BIO-TECHNE TECH public float $9.1B, Dec 31, 2025

Data on this page was fetched . The filing on SEC.gov is the record.